Press Release

Morgan Lewis Advises on $200 Million Revance Therapeutics Public Offering

September 19, 2022

NEW YORK, September 19, 2022: Morgan Lewis represented Goldman Sachs & Co. LLC, Cowen and Company LLC, and Guggenheim Securities LLC, as joint book-running managers of a $200 million upsized underwritten public offering of common stock by Revance Therapeutics, Inc.

Revance is a biotechnology company focused on elevating patient and physician experiences through the development, acquisition and commercialization of innovative aesthetic and therapeutic offerings.

The Morgan Lewis team included partner David Pollak, of counsel Thurston Hamlette, and associate Paul Lakkis, along with partners Louis Beardell, Jr., John Gorman, Kathleen Sanzo, Kenneth Kail, and associate Alexandre Gapihan.

For more, read the announcement.